ND Fargo의 비소세포폐암 임상 시험
비소세포폐암 관련 연구 14개가 Fargo 및 인근(약 30마일 이내) 지역에서 참여자를 모집하고 있습니다. 연구 항목을 열어 참여 자격 및 연구 팀 연락처를 확인하세요.
공식 연구 텍스트(영어)
연구 대상자를 모집 중이신가요? 이 페이지 상단에 노출하세요 — 30일 동안 $99 →
Testing the Addition of a Type of Drug Called Immunotherapy to the Usual Chemotherapy Treatment for Non-small Cell Lung Cancer, an ALCHEMIST Treatment Trial (Chemo-IO [ACCIO])
피험자 모집 중3상
- Sanford Broadway Medical Center, Fargo
- Sanford Roger Maris Cancer Center, Fargo
A Study of Targeted Post-Surgery Radiation Therapy for Non-Small Cell Lung Cancer With Remaining Lymph Node Cancer After Treatment
피험자 모집 중2상
- Sanford Broadway Medical Center, Fargo
- Sanford Roger Maris Cancer Center, Fargo
A Clinical Trial of Adjuvant Intismeran (V940) With or Without Pembrolizumab Coformulated With Berahyaluronidase Alfa (MK-3475A) in High-Risk Stage I Non-Small Cell Lung Cancer (V940-014)
피험자 모집 중3상
- Sanford Fargo Medical Center ( Site 3236), Fargo
Immunotherapy After Surgery for People Who Have No Remaining Cancer Cells After Standard Treatment for Early-Stage Non-Small Cell Lung Cancer, INSIGHT Trial
피험자 모집 중3상
- Essentia Health Cancer Center-South University Clinic, Fargo
- Sanford Broadway Medical Center, Fargo
- Sanford Roger Maris Cancer Center, Fargo
A Study to Assess Efficacy and Safety of Pembrolizumab With or Without Sacituzumab Tirumotecan (MK- 2870) in Adult Participants With Resectable Non Small Cell Lung Cancer (NSCLC) Not Achieving Pathological Complete Response (pCR) (MK-2870-019)
피험자 모집 중3상
- Sanford Fargo Medical Center-Roger Maris Cancer Center ( Site 0057), Fargo
KEYMAKER-U01 Substudy 01A: Efficacy and Safety Study of Pembrolizumab (MK-3475) With or Without Chemotherapy When Used With Investigational Agents in Treatment-naïve Participants With Stage IV Non-small Cell Lung Cancer (NSCLC) (MK-3475-01A/KEYMAKER-U01A)
피험자 모집 중1/2상
- Sanford Fargo Medical Center ( Site 0039), Fargo
KEYMAKER-U01 Umbrella Master Study: Studies of Investigational Agents With Either Pembrolizumab (MK-3475) Alone or With Pembrolizumab PLUS Chemotherapy in Participants With Non-small Cell Lung Cancer (NSCLC) (MK-3475-U01/KEYMAKER-U01)
피험자 모집 중관찰 연구
- Sanford Fargo Medical Center ( Site 0039), Fargo
A Study of Pembrolizumab With or Without Chemotherapy in Combination With Additional Treatments for Advanced Non-Small Cell Lung Cancer (NSCLC) (MK-3475-01G/KEYMAKER U01)
피험자 모집 중2상
- Sanford Fargo Medical Center ( Site 0039), Fargo
Autologous LN-145 in Patients With Metastatic Non-Small-Cell Lung Cancer
피험자 모집 중2상
- Sanford Roger Maris Cancer Center, Fargo
Comparing Combinations of Targeted Drugs for Advanced Non-Small Cell Lung Cancer That Has EGFR and MET Gene Changes (A Lung-MAP Treatment Trial)
피험자 모집 중2상
- Sanford Broadway Medical Center, Fargo
- Sanford Roger Maris Cancer Center, Fargo
Targeted Treatment for Advanced Non-Small Cell Lung Cancer That Has a MET Exon 14 Skipping Gene Change (An Expanded Lung-MAP Treatment Trial)
피험자 모집 중2상
- Sanford Broadway Medical Center, Fargo
- Sanford Roger Maris Cancer Center, Fargo
Adding the Immunotherapy Drug Cemiplimab to Usual Treatment for People With Advanced Non-Small Cell Lung Cancer Who Had Previous Treatment With Platinum Chemotherapy and Immunotherapy (An Expanded Lung-MAP Treatment Trial)
피험자 모집 중2/3상
- Essentia Health Cancer Center-South University Clinic, Fargo
- Sanford Broadway Medical Center, Fargo
- Sanford Roger Maris Cancer Center, Fargo
Assessing Benefits and Harms of Cannabis/Cannabinoid Use Among Cancer Patients Treated in Community Oncology Clinics
피험자 모집 중관찰 연구
- Essentia Health Cancer Center-South University Clinic, Fargo
SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
피험자 모집 중관찰 연구
- Massive Bio SYNERGY-AI site, Fargo
다른 도시의 비소세포폐암 시험
- Houston, TX연구 145개
- New York City, NY연구 120개
- Arlington, VA연구 104개
- Nashville, TN연구 97개
- Boston, MA연구 90개
- Los Angeles, CA연구 87개
- St. Louis, MO연구 73개
- Chicago, IL연구 61개
- Baltimore, MD연구 60개
- San Antonio, TX연구 59개
- Columbus, OH연구 56개
- Washington, DC연구 55개
Fargo의 다른 연구
- 폐암연구 13개
- 암 (전체)연구 10개
- 비만연구 9개
- 흑색종연구 9개
- 과체중연구 8개
- 전립선암연구 8개
- 대장직장암연구 7개
- 유방암연구 7개
- 두경부 편평세포암연구 6개
- 췌장암연구 6개
- 직장암연구 6개
- 결장암연구 6개
ClinicalTrials.gov 출처, 2026. 10. 5. 기준 데이터입니다. 각 연구는 자체적인 자격 기준을 설정하며, 연구 팀이 참여자를 결정합니다.